Kalvista Pharmaceuticals Inc (KALV)

Oct 14, 2025

Will a bounce in KalVista Pharmaceuticals Inc. offer an exitDay Trade & Daily Profit Focused Screening - newser.com

Oct 14, 2025

Oct 14, 2025

What drives KalVista Pharmaceuticals Inc 4XC1 stock priceMACD Histogram Signals & Rapid Portfolio Expansion - earlytimes.in

Oct 14, 2025

Oct 14, 2025

How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsTrade Volume Report & Fast Momentum Stock Entry Tips - newser.com

Oct 14, 2025

Oct 13, 2025

Ekterly eases most HAE attacks within 20 minutes, trial data show - Angioedema News

Oct 13, 2025

Oct 13, 2025

How sentiment analysis helps forecast KalVista Pharmaceuticals Inc.Gap Up & Low Risk Entry Point Guides - newser.com

Oct 13, 2025

Oct 13, 2025

Heatmap analysis for KalVista Pharmaceuticals Inc. and competitorsWeekly Profit Report & Consistent Return Strategy Ideas - newser.com

Oct 13, 2025

Oct 13, 2025

What makes KalVista Pharmaceuticals Inc. stock attractive to growth fundsQuarterly Market Review & Fast Gain Swing Alerts - newser.com

Oct 13, 2025

Oct 13, 2025

How to track smart money flows in KalVista Pharmaceuticals Inc.July 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com

Oct 13, 2025

Oct 10, 2025

Key resistance and support levels for KalVista Pharmaceuticals Inc.Weekly Profit Analysis & Real-Time Sentiment Analysis - newser.com

Oct 10, 2025

Oct 10, 2025

What Fibonacci levels say about KalVista Pharmaceuticals Inc. reboundDay Trade & AI Enhanced Execution Alerts - newser.com

Oct 10, 2025

Oct 10, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat

Oct 10, 2025

Oct 09, 2025

Can KalVista Pharmaceuticals Inc. stock sustain free cash flow growthGold Moves & Low Drawdown Momentum Trade Ideas - newser.com

Oct 09, 2025

Oct 08, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 08, 2025

Oct 07, 2025

KalVista: Prophylaxis Is Shrinking The Acute HAE TAM (NASDAQ:KALV) - Seeking Alpha

Oct 07, 2025

Oct 06, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 4%Should You Sell? - MarketBeat

Oct 06, 2025

Oct 06, 2025

KalVista’s oral HAE treatment shows rapid attack control in European trials - Investing.com

Oct 06, 2025

Oct 06, 2025

KalVista (KALV) Highlights Game-Changing Oral Treatment for HAE in German Study - GuruFocus

Oct 06, 2025

Oct 06, 2025

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY - Business Wire

Oct 06, 2025

Oct 06, 2025

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe - The Joplin Globe

Oct 06, 2025

Oct 06, 2025

KalVista Pharmaceuticals Appoints Bilal Arif as COO and Linea Aspesi as CPO - citybiz

Oct 06, 2025

Oct 06, 2025

Kalvista Pharmaceuticals, Inc. Appoints Bilal Arif as Chief Operating Officer, Effective October 6, 2025 - MarketScreener

Oct 06, 2025

Oct 06, 2025

KalVista Pharmaceuticals Names Bilal Arif as COO, Linea Aspesi as Chief People Officer - MarketScreener

Oct 06, 2025

Oct 06, 2025

KalVista Pharmaceuticals appoints new COO and CPO - Investing.com

Oct 06, 2025

Oct 06, 2025

KalVista Pharmaceuticals appoints new COO and CPO By Investing.com - Investing.com Australia

Oct 06, 2025

Oct 06, 2025

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer - The Globe and Mail

Oct 06, 2025

Oct 06, 2025

KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener

Oct 06, 2025

Oct 06, 2025

Can momentum traders help lift KalVista Pharmaceuticals Inc.Market Risk Report & Fast Moving Stock Watchlists - newser.com

Oct 06, 2025

Oct 05, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛

Oct 05, 2025

Oct 05, 2025

Tools to assess KalVista Pharmaceuticals Inc.’s risk profileWatch List & Consistent Growth Equity Picks - newser.com

Oct 05, 2025

Oct 05, 2025

Custom strategy builders for tracking KalVista Pharmaceuticals Inc.Oil Prices & Verified Technical Signals - newser.com

Oct 05, 2025

Oct 03, 2025

KalVista Pharmaceuticals Appoints Bethany Sensenig to Board - The Globe and Mail

Oct 03, 2025

Oct 03, 2025

Is KalVista Pharmaceuticals Inc. forming a bottoming base2025 Fundamental Recap & Daily Stock Momentum Reports - newser.com

Oct 03, 2025

Oct 03, 2025

Is KalVista Pharmaceuticals Inc. (4XC1) stock included in top ETFsWeekly Investment Report & Fast Moving Trade Plans - newser.com

Oct 03, 2025

Oct 02, 2025

KalVista Pharmaceuticals Appoints Bethany L. Sensenig to Board of Directors - citybiz

Oct 02, 2025

Oct 02, 2025

KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors - BioSpace

Oct 02, 2025

Oct 02, 2025

KalVista Pharmaceuticals appoints Bethany Sensenig to board of directors By Investing.com - Investing.com Nigeria

Oct 02, 2025

Oct 02, 2025

KalVista Pharmaceuticals appoints Bethany Sensenig to board of directors - Investing.com India

Oct 02, 2025

Oct 02, 2025

Voya Investment Management LLC Sells 2,151 Shares of KalVista Pharmaceuticals, Inc. $KALV - Defense World

Oct 02, 2025

Oct 01, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below 50-Day Moving AverageTime to Sell? - MarketBeat

Oct 01, 2025